Darolutamide Prolongs Overall Survival in nmCRPC
Darolutamide also improved secondary endpoints, including the time to pain progression, cytotoxic chemotherapy, and first symptomatic skeletal event.
Androgen-deprivation Therapy
Oral Antiandrogens Found to Increase Dementia Risk
In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.
Priorities in Prostate Cancer Care During the Pandemic
The authors of a new review discuss priorities, adjustments, and tailored approaches to prostate cancer management during the COVID-19 pandemic.
ADT Use Enables Delay in Prostate Cancer Radiation Therapy
Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.
Multimodality Treatment vs ADT Alone for Oligometastatic PCa Tied to Better Outcomes
Lower rates of cancer-specific mortality and castration-resistant disease observed when patients received multimodality treatment compared with ADT alone.
ADT May Decrease Risk of COVID-19 in Men With Prostate Cancer, Study Finds
TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.
Nonadherence to Abiraterone or Enzalutamide for Metastatic CRPC May Be More Common in Frail Patients
This observational cohort study found that BAAS questionnaire is not a suitable tool for monitoring whether older patients with mCRPC are adherent to their antiandrogen therapy; however, pill counting was effective.
Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Early ADT for Recurrent Prostate Cancer Challenged
Men with biochemically recurrent nonmetastatic prostate cancer following radical prostatectomy have long survival times from the time of surgery without hormonal treatment, a study found.
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
-
Loading...
-
Loading...
Next post in Prostate Cancer
